Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DR4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DR4 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View DR4 Products |
| Gene Delivery | DR4 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for cell-based apoptosis assays. |
View DR4 Products |
| Benchmark Ab | Anti-DR4 Recombinant Antibody Biosimilar based on Mapatumumab sequence. Recombinant positive control for binding and functional assays. |
View DR4 Products |
| Validator | DR4 siRNA Set Target-specific knockdown pool for functional validation and specificity screening. |
View DR4 Products |
| Related Target A | DR5 (TNFRSF10B) Sister death receptor. Crucial for cross-reactivity screening and bispecific agonist development. |
View DR5 Products |
| Related Target B | TRAIL (TNFSF10) Endogenous ligand. Used in competitive ligand-blocking assays and synergistic therapy studies. |
View TRAIL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-reactivity & Selectivity Screening (DR4 vs DR5/Decoy Receptors) | Human DR4, DR5, DcR1, and DcR2 ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Conformational Integrity for Agonist Screening | Lentiviral vectors for stable overexpressing cell lines, preserving native trimeric membrane conformation. |
| Lack of Benchmarking Controls | Mapatumumab-sequence biosimilar recombinant antibodies available as positive controls. |
| Target Specificity Verification | Sequence-verified siRNA sets included to confirm target-dependent apoptotic mechanisms. |
Live DR4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Death Receptor 4 (DR4/TNFRSF10A) is undergoing a major renaissance. While first-generation mono-specific agonistic monoclonal antibodies (such as Mapatumumab) demonstrated limited clinical efficacy due to insufficient receptor clustering, the next wave of drug discovery has shifted toward advanced modalities. Current R&D is heavily focused on multi-valent death receptor agonists, bispecific antibodies co-targeting DR4 and DR5, and DR4-directed Antibody-Drug Conjugates (ADCs) designed to leverage rapid receptor internalization for payload delivery.
As these next-generation molecules progress through clinical development, securing structurally sound antigens and robust cell-based assay systems is critical to validating receptor trimerization, internalization kinetics, and avoiding off-target decoy receptor binding.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Biotech & Pharma Consortia | Solid Tumors, Non-Small Cell Lung Cancer (NSCLC) | Internalization Assay (Requires high-purity ECD-Fc for conjugation and tracking) |
| Bispecific / Multi-specific Agonists | Inhibrx, Molecular Partners, AbbVie | Colorectal Cancer, Pancreatic Cancer | Selectivity Panel (Requires DR4, DR5, DcR1, and DcR2 proteins to rule out decoy binding) |
| Recombinant TRAIL Variants | Academic & Clinical Spin-offs | Hematological Malignancies | Competitive Ligand Binding (Requires high-purity recombinant TRAIL and DR4) |